Impaired trafficking of the very low density lipoprotein receptor caused by missense mutations associated with dysequilibrium syndrome  by Kizhakkedath, Praseetha et al.
Biochimica et Biophysica Acta 1843 (2014) 2871–2877
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrImpaired trafﬁcking of the very low density lipoprotein receptor caused
by missense mutations associated with dysequilibrium syndromePraseetha Kizhakkedath a, Anke Loregger b, Anne John a, Boris Bleijlevens b, Ali S. Al-Blooshi a,
Ahmed H. Al-Hosani a, Ahmed M. Al-Nuaimi a, Lihadh Al-Gazali c, Noam Zelcer b, Bassam R. Ali a,⁎
a Department of Pathology, College of Medicine and Heath Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates
b Department of Medical Biochemistry, Academic Medical Centre, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
c Department of Pediatrics, College of Medicine and Heath Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates⁎ Corresponding author at: Department of Pathology,
Sciences, United Arab Emirates University, P.O. Box 17666
Tel.: +971 3 7137470; fax: +971 3 7671966.
E-mail address: bassam.ali@uaeu.ac.ae (B.R. Ali).
http://dx.doi.org/10.1016/j.bbamcr.2014.08.013
0167-4889/© 2014 Elsevier B.V. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 29 May 2014
Received in revised form 18 August 2014
Accepted 22 August 2014
Available online 27 August 2014
Keywords:
VLDLR
Dysequilibrium syndrome
ERAD
Protein misfolding
ReelinDysequilibrium syndrome (DES, OMIM 224050) is a genetically heterogeneous condition that combines autoso-
mal recessive non-progressive cerebellar ataxia with mental retardation. The subclass dysequilibrium syndrome
type 1 (CAMRQ1) has been attributed to mutations in the VLDLR gene encoding the very low density lipoprotein
receptor (VLDLR). This receptor is involved in the Reelin signaling pathway that guides neuronalmigration in the
cerebral cortex and cerebellum. Three missense mutations (c.1459GNT; p.D487Y, c.1561GNC; p.D521H and
c.2117GNT; p.C706F) have been previously identiﬁed inVLDLR gene in patientswith DES. However, the function-
al implications of those mutations are not known and therefore we undertook detailed functional analysis to
elucidate the cellular mechanisms underlying their pathogenicity. The mutations have been generated by site-
directed mutagenesis and then expressed in cultured cell lines. Confocal microscopy and biochemical analysis
have been employed to examine the subcellular localization and functional activities of themutated proteins rel-
ative towild type. Our results indicate that the threemissensemutations lead to defective intracellular trafﬁcking
and ER retention of the mutant VLDLR protein. This trafﬁcking impairment prevents the mutants from reaching
the plasmamembrane and binding exogenous Reelin, the initiating event in Reelin signaling. Collectively, our re-
sults provide evidence that ER quality control is involved in the functional inactivation and underlying pathoge-
nicity of these DES-associated mutations in the VLDLR.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Dysequilibrium syndrome (DES, OMIM 224050) is a rare autosomal
recessive non-progressive cerebellar disorder characterized by ataxia,
mental retardation, cerebellar hypoplasia and delayed ambulation and
in some patients with strabismus, seizures and short stature [1]. DES is
inherited as an autosomal recessive trait and a subgroup of this disorder
has been associated with mutations in the gene encoding the very low
density lipoprotein receptor (VLDLR) and therefore recognized as
VLDLR-associated DES [2–8]. VLDLR is a multi-ligand apolipoprotein E
(ApoE) receptor and an integral part of the Reelin signaling pathway
that directs the proper positioning of migrating neuroblasts in the cere-
bral cortex and cerebellum during embryonic brain development [9].
Reelin is a glycoprotein secreted by the Cajal–Retzius cells and cerebel-
lar granule cells during cortical plate development, which directly bindsCollege of Medicine and Health
, Al-Ain, United Arab Emirates.to the extracellular domains of the VLDLR and the related low density li-
poprotein (LDL) receptor ApoER2 (LRP8) on the cell surface, triggering a
signaling cascade involving the intracellular adaptor protein Dab1, that
ultimately results in the cortical layer formation in the developing brain
[10,11]. VLDLR and ApoER2 mediate canonical Reelin signaling and
deletion of the genes encoding both these receptors in mice results in
inversion of cortical layers and absence of cerebellar foliation [12]. Con-
sistent with the ﬁndings in animal models with VLDLR homologue
knock-outs, a small compact cerebellum and absence of foliation have
been observed in MRI images of brains of patients with VLDLR muta-
tions associated with DES [2,4,13,14].
Structurally, VLDLR is a type I transmembrane receptor belonging to
the LDL receptor family. Like the other members of this family, VLDLR
has ﬁve highly conserved structural domains as shown in Fig. 1A. An
extracellular N-terminal ligand binding domain with cysteine-rich
repeats, six modules of amino acids containing YWTD motif which
form the extracellular β-propeller domain, an epidermal growth factor
(EGF) domain, an O-linked sugar domain, a single transmembrane
sequence and a cytoplasmic region containing an NPxY motif [15].
VLDLR mRNA transcripts are highly abundant in the brain and fatty
Fig. 1. Schematic domain structure of VLDL receptor: (A) The VLDLR extracellular domain contains eight cysteine rich class A repeats (1–8), three EGF-like repeats (A–C), six YWTD
modules (I–VI) forming a β-propeller domain and an O-linked sugar domain. The positions of disease causing mutations are indicated by asterisks. (B) Homology model of the VLDLR
as predicted by the Phyre2 Protein Fold Recognition Server [44]. VLDLR protein was modeled in intensive mode. Residues 69–752 (78% of the submitted sequence) of the VLDLR were
modeled with 100% conﬁdence using the LDLR structure (PDB identiﬁer 1N7D) as a structural template. Structural predictions for the propeller domain (residues 439–697) and subse-
quent EGF domain (residues 702–750) are shown on the left with the mutated residues as spheres. Homologous conserved residues in the LDLR structure are indicated on the right.
Figure was prepared using PyMOL [45].
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its roles in neuronal signaling and fatty acid metabolism [16].
Several mutations in VLDLR associated with DES are null mutations
involving either complete deletion of the gene or loss of functional
alleles resulting from premature stop codons, a frameshift or missense
mutations. Regardless of the lesion type, the consequence of VLDLR
loss-of-function is indistinguishable at the neuroanatomical level
[3,5,6,13] suggesting that the brain abnormality resulting from
VLDLR deﬁciency is likely to be caused by impaired Reelin signaling.
We have identiﬁed the ﬁrst homozygous missense founder mutation
(RefSeq NM_003383.3:c.2117GNT; NP_003374.3: p.C706F) in VLDLR
to cause DES in two unrelated Omani families from UAE [13]. Two
other pathogenic missense mutants P.D487Y [17] and p.D521H [5],
also located in the highly conserved extracellular β-propellar do-
main of VLDLR, have been recently described (Fig. 1A). Intriguingly,
these residues are also conserved in the closely related receptor,
the LDLR. Moreover, structural analysis indicates their positioning
in these receptors is similar, likely reﬂecting a conserved function
(Fig. 1B). It has been proposed that the functional loss associated with
mutations at these key residues is likely a result of misfolding, ER reten-
tion and subsequent degradation by the ER associated degradation
pathways [5,13,17]. However, the exact cellular mechanisms underly-
ing these pathogenic mutations have not been established and are
therefore investigated in this study.
2. Materials and methods
2.1. Antibodies
The antibodies with their dilutions and sources were as follows:
antibodies for immunoﬂuorescence: mouse anti-HA-tag monoclonal an-
tibody (1:200; Cell Signaling Technology), rabbit anti-calnexin polyclonal
antibody (1:200, Santa Cruz), mouse anti-Reelin (1:200, Millipore clone
G10), Alexa Fluor 568-goat anti-mouse IgG (1:200; Molecular Probes),
Alexa Fluor 568-goat anti-rabbit IgG (1:200; Molecular Probes), AlexaFluor 488-goat anti mouse IgG (1:200, Molecular Probes). Antibodies
for Western blotting: rabbit anti-HA polyclonal antibody (1:4000,
Sigma), goat anti-rabbit IgG-peroxidase (1:30,000; Sigma), rabbit
anti-mouse IgG-peroxidase (1:30,000; Sigma).
2.2. Generation of mutant expression constructs
All the mutations described in this study are with reference to the
coding VLDLR sequence represented by Genebank accession number
NM_003383.3 and protein sequence represented by NP_003374.3. The
missense mutations (p.D487Y, p.D521H, p.C706F) were introduced into
the C-terminally tagged VLDLR-HA expression vector [18] by site direct-
edmutagenesis using PfuUltra HF polymerase (Stratagene). The primers
used to introduce the mutations were as follows: VLDLR- D487-F: CAGA
AACTATTCTGGGCCTACCTAAGCCAAAAGGCTATC; VLDLR-D487Y-R:
GATAGCCTTTTGGCTTAGGTAGGCCCAGAATAGTTTCTG; VLDLR-D521H-F:
CTGCAGCCATTGCTGTTCACTGGGTGTACAAGACCATC; VLDLR-D521H-R:
GATGGTCTTGTACACCCAGTGAACAGCAATGGCTGCAG; VLDLR-C706F-F:
CCATCAGGTAAAAATTGGTTCGAAGAAGACATGGAGAATG; and VLDLR-
C706F-R: CATTCTCCATGTCTTCTTCGAACCAATTTTTACCTGATGG. All the
plasmids have been sequenced to conﬁrm the introduction of intended
changes. Sequencing was performed using the dideoxy Sanger method
by ﬂuorescent automated sequencing on an ABI 3130xl genetic analyzer
(Applied Biosystems).
2.3. Cell culture and transfection
HeLa cells were cultured in DMEM (Invitrogen) supplemented with
10% fetal bovine serum, 2 mM L-glutamine and 100 U/ml penicillin/
streptomycin at 37 °C with 5% CO2. For localization experiments, cells
were grown on sterile cover slips in 24-well tissue culture plates and
transient transfection was performed by FuGENE HD transfection re-
agent (Promega) according to the manufacturer's instructions using
0.5 μg plasmid DNA. GFP-H-Ras plasmid [19] was used as a plasma
membrane marker and co-transfected with HA-tagged wild type [18]
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after 24 h of transfection.
Human embryonic kidney cells (HEK-293T, ATCC) were cultured in
Dulbecco's modiﬁed Eagle's medium/F12 medium (Invitrogen) supple-
mented with 10% fetal bovine serum (Invitrogen), penicillin (10 U/ml)
and streptomycin (100 μg/ml) at 37 °C with 5% CO2. For transfection,
cells were grown in 6 well tissue culture plates and transfected with
1 μg plasmid DNA using FuGENE HD transfection reagent.
Reelin-conditioned medium was prepared as previously reported
[18]. Brieﬂy, HEK-293T cells stably expressing Reelin (a kind gift from
Dr. Thomas Curran, Children's Hospital of Philadelphia) [20] were
grown to ~75% conﬂuence, washed twice with phosphate-buffered sa-
line and cultured in Opti-MEM medium (Invitrogen) for an additional
24 h. Conditionedmediumwas collected, ﬁltered, and stored at−80 °C.
2.4. Immunocytochemistry and imaging
Twenty-four hours after transfection, HeLa cells grownon cover slips
were washed with phosphate-buffered saline (PBS), ﬁxed by methanol
at−20 °C for 5 min. Fixed cells were washed with PBS three times and
blocking was carried out in 1% BSA (Sigma) in PBS for 30 min at room
temperature. After blocking, the cells were incubated with either
mouse monoclonal anti-HA antibody alone or co-stained with both
mouse monoclonal anti-HA antibody and rabbit polyclonal anti-
calnexin antibodies, for 45 min at room temperature. The cells were
washedwith PBS, and incubatedwith the respective secondary antibod-
ies for 45min at room temperature, washed several times with PBS and
mounted in immunoﬂuor medium (ICN Biomedicals). Confocal micros-
copy and imaging was performed with a Nikon Eclipse system (Nikon
Instruments Inc) equipped with FITC and TRITC ﬁlters. Images were
obtained with 100× oil immersion objective lens. All images presented
are single sections in the z-plane. Images were color enhanced and
merged using ImageJ software [21].
2.5. Immunoprecipitation and Western blotting analysis
Forty eight hours after transfection, HEK-293T cells were lysed in
CelLytic-M lysis reagent (Sigma) containing protease inhibitors
(Sigmafast protease inhibitor cocktail, Sigma) according to the
manufacturer's instructions. Total protein concentration was deter-
mined by Bicinchoninic Acid protein Assay (BCA kit, Pierce). HA tagged
proteins were immunoprecipitated using anti-HA agarose beads
(Pierce). Brieﬂy, equal amounts of total cell lysates were incubated
with anti-HA agarose beads for 2 h at 4 °C with rotation. Immunoprecip-
itates were collected by centrifugation and washed thrice with lysis
buffer. For Western blotting, the proteins were eluted from the beads
by boiling in Laemmli sample buffer. The samples were then resolved
on 7.5% SDS-PAGE gel followed by blotting onto nitrocellulose mem-
branes (WhatmanProtran) andprobedwith respective antibodies. Detec-
tion was performed using Enhanced Chemiluminescence Plus reagent
(Pierce) and Typhoon FLA 9500 Imager (GE Healthcare Biosciences).
2.6. Endoglycosidase H sensitivity assay
For Endoglycosidase H deglycosylation assay, the immunoprecipi-
tates were denatured in 1× glycoprotein denaturation buffer (0.5%
SDS and 1%β-mercaptoethanol) for 5min at 100 °C. The denatured pro-
teins were then divided into two equal aliquots, which were incubated
for 4 h at 37 °C in the presence or absence of 10 U of Endoglycosidase H
(Sigma). The digested samples were then resolved on a 7.5% SDS-PAGE
gel and analyzed by Western blotting as described above.
2.7. Reelin binding assay
Reelin binding assay was performed as described in [18]. Brieﬂy,
HEK-293T cells were transfected with the different VLDLR expressionplasmids. Subsequently, 48 h post-transfection, cells were washed
thrice with Opti-MEM (Invitrogen) and incubated with Reelin-
containing conditioned media on ice. Binding was allowed to proceed
for 30 min after which cells were vigorously washed ﬁve times with
PBS. Preparation of cell lysates and immunodetection was done as
detailed above.
3. Results
3.1. The three missense mutations affect the trafﬁcking and cell surface
expression of VLDLR
To investigate the impact of the mutations at the cellular level, we
generated by site directed mutagenesis the three missense mutations
(P.D487Y, p.D521H and p.C706F) found in DES patients. To determine
the subcellular localization of the mutant receptors, the constructs
were co-expressed in HeLa cells along with the plasma membrane
indicator, H-Ras tagged with EGFP [19]. The wild type HA-tagged
VLDLR localized largely to the plasma membrane as conﬁrmed by its
co-localization with GFP-H-Ras (Fig. 2, panels A–C). The intracellular
localization patterns of the three DES-associated VLDLR mutants were
distinct from that of the wild type and showed a more cytoplasmic,
reticular and perinuclear distribution, which is characteristic for ER
localized proteins (Fig. 2, panels D–L). To conﬁrm the ER localization
of the mutants, HeLa cells over-expressing wild type or mutants were
co-stained with the ER marker, calnexin. As apparent from panels A–C
in Fig. 3, the localization pattern of the wild type receptor was distinct
from the staining of calnexin. A small fraction of the wild type protein
was also found to co-localizewith calnexin, which likely reﬂects nascent
synthesized protein in transit. All the three mutants showed co-
localization with calnexin (Fig. 3, panels D–L).
3.2. Altered glycosylation status conﬁrms ER retention of VLDLR mutants
The mature form of type-1 VLDLR contains two types of carbohy-
drates, N-linked and O-linked sugars. Hence type 1 VLDLR is detected
as two bands in immunoblots, a faster migrating precursor form and a
slower migrating fully glycosylated mature form [22]. In total cell ly-
sates overexpressing the wild type VLDLR, a precursor form of apparent
molecular weight 130 kDa and a mature form of apparent molecular
weight 150 kDa were observed (Fig. 4). In cell lysates overexpressing
the mutants the mature receptor formwas absent and only the precur-
sor form was observed. To analyze the glycosylation status of the mu-
tant and wild type VLDLR, immunoprecipitated wild type and mutant
proteins were subjected to Endoglycosidase H digestion (Endo H),
which speciﬁcally removes oligosaccharides of the high mannose and
hybrid (pre-Golgi) forms, but not complex carbohydrate structures
attained in the Golgi. Figure 4 shows that Endo H treatment reduced
the molecular mass of the mutant VLDLRs, as well as of the precursor
form of the wild type receptor. The higher molecular weight form ob-
served in the wild type VLDLR was however resistant to EndoH treat-
ment, consistent with it representing advanced glycosylation status
attained in the Golgi. Taken together with the localization studies, this
result establishes that the mutant receptors are retained in the ER,
explaining also the absence of complex Golgi-dependent glycosylation.
3.3. Mutant forms of VLDLR fail to bind Reelin
VLDLR is one of the receptors for Reelin, an extracellular matrix pro-
tein that directs the organization of cortical structures in the developing
cerebral cortex and cerebellum. Binding of Reelin to the lipoprotein re-
ceptors on the cell surface is a prerequisite for triggering the canonical
Reelin signaling pathway in migrating neurons. Therefore, ER retention
and subsequent degradation of VLDLR is likely to disrupt Reelin signal-
ing mediated by VLDLR. To test this possibility we incubated HEK-293T
cells expressing wild type or mutant VLDLR with Reelin-containing
Fig. 2. Comparison of intracellular localization of VLDLR wild type andmutant variants in relation with plasma membranemarker H-Ras: HeLa cells were transiently co-transfected with
the indicated HA-tagged VLDLR plasmids and EGFP tagged H-Ras and stained with anti-HA antibodies. (A), (D), (G) and (J) show the distribution of over-expressed HA-tagged VLDLR
proteins. (B), (E), (H) and (K) show the localization pattern of GFP-H-Ras, which is on the plasma membrane. (C), (F), (I) and (L) are the composite images indicating the extent of
co-localization of VLDLR proteins with GFP-HRas. Scale bar is 20 μM.
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munoblotting, as previously reported [18]. Consistentwith our previous
ﬁnding, Fig. 5 shows that only the Endo H resistant mature form of
VLDLR found in the wild type reaches the plasma membrane and is
able to bind Reelin. In agreement with their subcellular localization,
the ER retained forms of VLDLR failed to bind extracellular Reelin
(Fig. 5), suggesting that all the three missense mutations result in func-
tionally inactive receptors in vivo.
4. Discussion
In this report we have analyzed the cellular consequences of three,
recently identiﬁed [5,13,17], missense mutations in the VLDLR geneassociated with DES. We provide evidence that these mutations lead
to a dysfunctional receptor due to ER retention of the mutant receptors
that precludes it from reaching the plasma membrane and binding
Reelin.
The disease-causing mutations p.D487Y and p.D521H affect amino
acid residues in the conservedβ-propeller domain (Fig. 1A, B). The crys-
tal structure of the closely related receptor, LDLR revealed that in the
consensus repeat motifs (Tyr-Trp-Thr-Asp), the Asp residues serve as
clasps between adjacent blades of the β-propeller, stabilizing the struc-
ture by hydrogen-bonding with the backbone and Trp side chains [23].
Since both the carboxylated oxygens of Asp residues are acceptors of
structurally conserved hydrogen bonds, the pathogenic mutations will
probably disrupt the structure and subsequently, trafﬁcking of the
Fig. 3. Comparison of intracellular localization of VLDLRwild type andmutant variants in relationwith the ERmarker calnexin: HeLa cells transiently transfectedwith the indicated HA-tagged
VLDLR constructs were ﬁxed and co-stainedwith antibodies against HA-tag and calnexin. (A), (D), (G) and (J) show the intracellular distribution of over-expressed HA-tagged VLDLR proteins.
(B), (E), (H) and (K) show the intracellular localization of the ER resident protein calnexin. (C), (F), (I) and (L) are themerged images showing the extent of co-localization of VLDLR proteinwith
calnexin. For presentation purpose images A, D, G and J were pseudocolored as red and images B, E, H and K were pseudocolored as green using image J software. Scale bar is 20 μM.
Fig. 4. Endoglycosidase H (EndoH) susceptibility of the wild-type VLDLR and its mutants: HA-tagged wild type VLDLR or mutant variants were transiently expressed in HEK-293T cells. HA-
tagged proteinswere immunoprecipitated, treatedwith Endoglycosidase H for 4 h at 37 °C (+) or left untreated for 4 h at 37 °C (−) and analyzed by immunoblottingwith anti-HA antibody.
The mature form of the receptor was detectible only in the immunoprecipitates from the wild type. ER forms of the wild type as well as the mutants were sensitive to EndoH treatment.
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Fig. 5. Defective cellular trafﬁcking of the VLDLR disrupts Reelin binding: HEK-293T cells were transfected with the indicated HA-tagged VLDLR expression plasmids. A GFP-encoding
expression plasmid was co-transfected and served to control transfection efﬁciency. Subsequently, cells were incubated with Reelin-containing conditioned medium for 30 min on ice
followed by extensive washing. Total cell lysates were subjected to SDS-PAGE and immunoblotted as indicated.
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EGF-like 3 domain of theVLDLR protein. The cysteine residue at position
706 is highly conserved and is predicted to be involved in a disulﬁde
bond with cysteine 719. Therefore, disruption of this residue is likely
to result in misfolding of the protein. These three residues (D487,
D521, C706) are also conserved in the LDLR (D424, D461, C646), and
homology modeling indicates that their positioning in the VLDLR and
LDLR is highly similar (Fig. 1B). Intriguingly, mutations occurring in
the corresponding positions in LDLR have been reported to cause
familial hypercholesterolemia (FH) [24,25]. We show here that all the
pathogenic amino acid substitutions reported in VLDLR indeed result
in the retention of themutant variants in the ER and impaired transport
to the cell surface, likely due to misfolding. In contrast, the wild type
protein localized predominantly to the plasma membrane, with only a
smaller fraction observed in the ER. Biochemical analysis of themutants
and wild type protein conﬁrmed their intracellular distribution. The ER
has a quality control system to ensure that only correctly folded proteins
reach their ﬁnal destination. Incompletely folded or misfolded proteins
are retained in the ER, eventually translocated to the cytoplasm and de-
graded by the ubiquitin proteasome pathway, a process collectively
termed as ER-associated degradation (ERAD) [26]. Alternatively,
prolonged retention ofmisfolded proteins in the ER can induce ER stress
and initiate macroautophagy, via an ER-activated autophagy (ERAA)
pathway [27]. Retention of misfolded proteins in ER and subsequent
degradation by ERAD has been implicated in the pathogenicity of
many congenital disorders [28–31]. Mutations that generate transport
deﬁcient variants of LDLR, account for ~50% of the pathogenic variants
causing FH, and proteasomal degradation has been reported to be the
principal pathway for the degradation of many of LDLR mutants [32].
Functionally, VLDLR deﬁciency at the cell surface could translate to
impaired binding of the receptor to its corresponding ligands in speciﬁc
cell types. VLDLR appears to play a crucial role in triglyceride metabo-
lism [33] and is an integral part of the Reelin signaling pathway which
guides neuronal migration in the cerebral cortex and cerebellum [34].
Reelin-Dab1 signaling has been found to regulate changes in Golgi
morphology in neurons that drive neuronal polarization and brain
lamination [35]. Reelin signaling is regulated through internalization
and rapid uncoupling of the ligand from the VLDL receptor, whereupon
the ligand is targeted for lysosomal degradation and the receptor is
recycled to the cell membrane [36]. The neurodevelopmental pheno-
type in DES has been attributed to defects in Reelin signaling since mu-
tations in the other components of this pathway have also been
reported to produce identical phenotypes to VLDLR receptor deﬁciency
[5,37]. Our results from in vivo Reelin binding assay indicated that, ERretention of the mutant variants of the VLDLR indeed lead to impaired
binding to Reelin.
Recently it has been reported that Reelin also mediates signals via a
non-canonical pathway in the post-natal brain which does not involve
the VLDLR/ApoER2 receptors [38]. A few reports suggest that processes
related to neuronal migration including maturation and secretion of
Reelin are sensitive to purtubations in the ER quality control (ERQC)
machinery, since mutations affecting the integral components of the
ERQC has been found to result in cortical dysplasia in animals [39,40].
Chronic ER stress due to persistent accumulation of misfolded proteins
has also been linked to the pathogenesis of several neurodegenerative
diseases [41]. A recent study indicates that VLDLR itself may be an im-
portant component of the ER stress responsive pathway since increased
expression of VLDLR transcripts has been observed in response to ER
stress [42] and also conditions that promote ER stress such as hypoxia
[43].
In conclusion, our results indicate that ER retention is involved in the
pathogenic mechanism leading to DES by the VLDLR missense muta-
tions studied here. The possibility of restoring the functionality of
mutant proteins that are entrapped in the ER due to folding disabilities
is being explored as a therapeutic approach for several human genetic
diseases, and could be potentially implemented for treatment of DES.
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